Lipids News and Research

RSS

Lipids are a broad group of naturally-occurring molecules which includes fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), monoglycerides, diglycerides, phospholipids, and others. The main biological functions of lipids include energy storage, as structural components of cell membranes, and as important signaling molecules.

Greater access to rehabilitation after TIA can prevent future strokes, says researcher

Transient Ischemic Attacks (TIA) are often called "mini strokes" for good reasons -- the short-term symptoms can mimic a stroke and up to 10 percent of first-time sufferers often experience full-blown strokes within as little as 90 days. Despite the well-known statistics, no post-TIA regimen exists to help prevent future strokes -- but this might be changing.

25 Feb 2010

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association.

24 Feb 2010

Winner of 2010 Anatrace Membrane Protein Award

Affymetrix, Inc. today announced that Professor Tom Rapoport of Harvard Medical School and Howard Hughes Medical Institute is the winner of the 2010 Anatrace Membrane Protein Award.

24 Feb 2010

WCMC-Q students receive new round of UREP funds totaling $280,000

Twenty-eight WCMC-Q students have received grants totaling $280,000 in the latest, seventh, round of funding from the Undergraduate Research Experience Program (UREP) to conduct advanced research projects with faculty members.

22 Feb 2010

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

ATM, a protein that reacts to DNA damage by ordering repairs or the suicide of the defective cell, plays a similar, previously unknown role in response to oxidative damage outside of the nucleus, researchers report this week in the online version of the Proceedings of the National Academy of Sciences.

19 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

Treating bacteria with insufficient levels of antibiotics leads to multidrug resistance in 'superbugs'

For years, doctors have warned patients to finish their antibiotic prescriptions or risk a renewed infection by a "superbug" that can mount a more powerful defense against the same drug. But a new study by Boston University biomedical engineers indicates that treating bacteria with levels of antibiotics insufficient to kill them produces germs that are cross-resistant to a wide range of antibiotics.

12 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

EVMS researchers identify source that causes Type 1 diabetes

Doctors at Eastern Virginia Medical School's Strelitz Diabetes Center have been stalking the culprit responsible for Type 1 diabetes. Now, they are one step closer.

5 Feb 2010

American Heart Month aims to spread awareness of women and heart disease

More than five times as many women are diagnosed with heart disease each year than with breast cancer. American Heart Month in February aims to spread awareness of women and heart disease, and one Alabama company has found the quickest way to a woman's heart might be through her gynecologist.

5 Feb 2010

Pioneering paper claims Earth's chemical energy powered early life

For 80 years it has been accepted that early life began in a 'primordial soup' of organic molecules before evolving out of the oceans millions of years later. Today the 'soup' theory has been over turned in a pioneering paper in BioEssays which claims it was the Earth's chemical energy, from hydrothermal vents on the ocean floor, which kick-started early life.

3 Feb 2010

Normal protein can be converted into prion that causes fatal brain diseases in humans

Scientists have determined how a normal protein can be converted into a prion, an infectious agent that causes fatal brain diseases in humans and mammals.

29 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Humans' evolutionary advantage also makes them susceptible to cancer, dementia and heart disease

The same evolutionary genetic advantages that have helped increase human lifespans also make us uniquely susceptible to diseases of aging such as cancer, heart disease and dementia, reveals a study to be published in a special PNAS collection on "Evolution in Health and Medicine" on Tuesday, Jan. 26.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

Besides LDL, Lp(a) can also increase risk for heart disease

LDL isn't the only "bad boy" when it comes to cholesterol. According to a new study, a lipoprotein in the bloodstream called Lp(a) — pronounced "LP little A" — can be labeled "bad cholesterol."

20 Jan 2010

Scientists publish study on the effects of nutritional supplement ingredients on cholesterol levels

In collaboration with the scientists in the Department of Animal Sciences at the University of Wisconsin-Madison, Standard Process scientists have published a study examining the effects of nutritional supplement ingredients on cholesterol levels in Rapacz familial hypercholesterolemic swine or FH swine.

19 Jan 2010

Lipids News and Research

Further Reading

Greater access to rehabilitation after TIA can prevent future strokes, says researcher

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

Winner of 2010 Anatrace Membrane Protein Award

WCMC-Q students receive new round of UREP funds totaling $280,000

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Treating bacteria with insufficient levels of antibiotics leads to multidrug resistance in 'superbugs'

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

EVMS researchers identify source that causes Type 1 diabetes

American Heart Month aims to spread awareness of women and heart disease

Pioneering paper claims Earth's chemical energy powered early life

Normal protein can be converted into prion that causes fatal brain diseases in humans

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Humans' evolutionary advantage also makes them susceptible to cancer, dementia and heart disease

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

The American Journal of Pathology: Highlights from February 2010 issue

Health Canada approves Novartis' Afinitor to treat patients with mRCC

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Besides LDL, Lp(a) can also increase risk for heart disease

Scientists publish study on the effects of nutritional supplement ingredients on cholesterol levels

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo